Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on BeiGene (ONC – Research Report) on February 28 and set a price target of $311.00.

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that ...

Get Our Latest Research Report on ONC Beigene Trading Down 9.7 % The firm has a market cap of $24.03 billion, a PE ratio of -29.80, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63. The ...

SAN MATEO, Calif., February 25, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...

Beigene has a one year low of $126.97 and a one year high of $287.88. The firm has a market capitalization of $24.03 billion, a P/E ratio of -29.80, a P/E/G ratio of 7.73 and a beta of 0.63.

BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

We raise our fair value estimate for no-moat BeiGene to HKD 149 per share from HKD 132, based on better-than-expected Brukinsa sales in the last quarter and a faster ramp-up going forward.

BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates ...